Search for dissertations about: "chimeric antigen receptor T CAR-T cells"
Showing result 1 - 5 of 12 swedish dissertations containing the words chimeric antigen receptor T CAR-T cells.
-
1. Cancer Immunotherapy : Oncolytic viruses and CAR-T cells
Abstract : Various forms of cancer immunotherapy have developed rapidly with improved survival and quality of life for cancer patients. Cancer immunotherapy aims to educate the patient’s immune system to eliminate cancer cells, including immune checkpoint inhibitors (ICIs), adoptive cell transfer (mostly T cells), oncolytic viruses (OVs) and cancer vaccines. READ MORE
-
2. CAR T cells for Immunotherapy of Cancer
Abstract : In recent years, immunotherapy has revolutionized cancer treatment by prolonging survival and even curing patients lacking other available therapies. Besides immune checkpoint inhibitors, one of the major advances is attributed to the success of chimeric antigen receptor (CAR)-T cell therapy in treating patients with B-cell malignancies. READ MORE
-
3. Cancer Immunotherapy : Evolving Oncolytic viruses and CAR T-cells
Abstract : In the last decade cancer immunotherapy has taken huge strides forward from bench to bedside and being approved as drugs. Cancer immunotherapy harnesses the power of patient’s own immune system to fight cancer. READ MORE
-
4. The Multiple Faces of Genetically-Modified T Cells : Potential Applications in Therapy
Abstract : In this PhD thesis the potential of T-cells as therapy for disease are explored. The applications of genetically modified T-cells for treatment of cancer and autoimmune disease; the functionality and optimal activation of T-cells are discussed. READ MORE
-
5. Defining the potential of mesothelin-directed CAR T cells for the treatment of ovarian cancer
Abstract : Chimeric antigen receptor (CAR) T cells have revolutionized the field of immunotherapy, by redirecting T cell specificity and effector functions. Co-stimulation has proven to be crucial for therapeutic effectiveness of CAR T cells and remarkable clinical response rates have been achieved with second generation CD19-directed CAR T cells containing either a CD28 or 4-1BB co-stimulatory domain for the treatment of B cell malignancies. READ MORE